A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

Herbert Y. Meltzer, Stefania Bonaccorso, William V. Bobo, Yuejin Chen, Karuna Jayathilake

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method:This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F-4,F-434=4.7), body mass index (BMI) (F-4,F-424=5.1), glycosylated hemoglobin (HgbA1c) (F-4,F-427=4.3), total cholesterol (F-4,F-429=4.4), TG (F-4,F-426=5.9), and TG/HDL-C ratio (F-4,F-426=4.3) (P
Original languageEnglish
Pages (from-to)1602 - 1610
Number of pages9
JournalJournal of Clinical Psychiatry
Volume72
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Dive into the research topics of 'A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation'. Together they form a unique fingerprint.

Cite this